Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces mean body weight reductions of 20.9% at 72 weeks by delaying gastric emptying, suppressing ghrelin rebound, and enhancing glucose-dependent insulin secretion
Until today, no medication is approved for the treatment of this disease
products often lack quality control, raising fears of contamination, incorrect dosing, or dangerous ingredients, with the FDA warning against compounding it due to insufficient safety data
Indeed, it has to be considered that oral hyaluronic acid supplementation, which could further improve the compliance of treatment, has to be evaluated in terms of bioavailability and absorption considering that the size of the molecule and its breakdown during digestion which could affect its therapeutic potential [53,54]